DISCUSSION OF PATHOLOGY
Bowen's disease (BD) is a pre-invasive squamous cell carcinoma in situ. It was first described by JT Bowen in 1912 as a precancerous dermatosis. (1) The eventual risk of progression to invasive squamous cell carcinoma and metastatic disease in a Bowen's is 3% to 5% for cutaneous Bowen's while it is up to 10% for genital Bowen's disease. (2) The aetiological factors contributing to development of Bowen's Disease include solar and UV radiation, arsenic exposure, radiotherapy, immunosuppression, HPV and other Polyomavirus infection. Association with autoimmune diseases such as Sjogren's syndrome has been noted; however, no causation has been proven. (3) Bowen's Disease is most commonly seen in elderly individuals and on sun-exposed sites such as head and neck and the upper limbs. (3) The appearance of Bowen's Disease on the extensor aspect of the arm in our patient, who is above 60 years of age is in keeping with most literature for solar/UV radiation induced pre-invasive NMSC. A study describing the distribution of Bowen's Disease with respect to age, sex and site noted that Bowen's Disease in lower limbs and of the cheek was most often seen in women than in men. (4) Bowen's Disease can occur on any keratinised skin and has been reported from trunk and genitalia. The other less frequent sites of involvement are lip, nipple, palm, feet and nail bed. (5) Lesions on the trunk should raise the suspicion of chronic arsenic exposure.
The usual clinical presentation of Bowen's Disease is a single erythematous scaly or crusted plaque, which enlarges slowly over time. The scales are easily detachable, margins are well defined and it may be slightly raised. (3) Our patient presented with the classical clinical features of a gradually increasing scaly plaque. Other morphological patterns reported in literature are verrucous plaque, pigmented Bowen's disease (PBD). Pigmented Bowen's Disease constitutes 2% of BD cases, is more common in genital and interdigital sites, however, other sites such as digits, lip, umbilicus have all been reported. Clinically, Pigmented Bowen's Disease can mimic melanoma in situ. (6) Bowen's Disease usually presents as a single lesion; however, cases of multicentric Bowen's have been seen. The probable aetiology of arsenic exposure or immunosuppression should be considered in such cases. (7) Dermoscopy of Bowen's Disease shows 2 predominant features namely vascular patterns and scaly surface. The vascular pattern may be glomerular vessels or dotted. Pigmentary features of small brown or black globules, streaks and structure less (homogenous) pigmentation may be seen in PBD. (8, 9) Histopathology of Bowen's Disease shows complete disarray of keratinocytes in the epidermis, with crowded atypical keratinocytes, large, multilobulated, hyperchromatic nuclei, and atypical mitoses, giving a windblown appearance. The basement membrane is intact with no dermal invasion. The vessels in the papillary dermis may be dilated and associated with inflammatory infiltrate. (10, 11) PBD shows the presence of increased melanin in basal layer and melanophages in the dermis. Many variants have been described in literature, such as psoriasiform, atrophic, papillated, clear cell, pagetoid and mucinous or sebaceous. (3) The possibility of Bowen's Disease being a marker for internal malignancy has also been considered. There are reports of association with lung and liver carcinoma. However, studies have not substantiated the association. The association of internal malignancy in a case of BD is higher when it is due to arsenic exposure or immunosuppression. (12) 
DISCUSSION OF MANAGEMENT
The prognosis for Bowen's Disease in general is excellent since it is a slow growing lesion and responds well to treatment. There are many treatment modalities available including surgical excision, Mohs surgery, curettage, cryotherapy, photodynamic therapy, topical 5-fluorouracil and topical imiquimod. (13) There are rare case reports of selfresolving Bowen's Disease. (14) Surgical modality has been the most commonly used modality in both UK and Australia. (15) It is recommended for size and sites where it is convenient and has the benefit of being a rapid, easy and cost effective method. For lesions on face, genital and digital lesions, Mohs surgery can be considered if feasible. (16) Curettage with cautery, less often used, is another simple economical modality of treatment. The success of it; however, depends on the skill of the performing physician. The response is comparable to cryotherapy with the benefit of less pain and lower recurrence rates. (14, 15) Cryotherapy with liquid nitrogen is a simple method of treatment with the advantage of accessibility in outpatient setting. The clearance rates to cryotherapy varies considerably. It is said to be comparable to topical 5-FU. Pain and blistering and ulceration are common side effects. (16) Photodynamic therapy with 5-aminolevulinic acid (ALA) or methyl aminolevulinate (MAL) has very good clearance rates of 93% even with single cycle, comparable to curettage, cryotherapy and 5-FU. (13, 15, 17) From currently available data, it has high level of evidence for its use in BD. It may be especially useful for larger lesions, difficult to treat or resistant sites such as the lower limbs. (15) Topical 5-fluorouracil 5% cream has shown clearance rates up to 92% in both short and longterm followup studies. Variable clearance rates are related to the different continuous and pulse therapy regimens of 5-FU. Topical imiquimod, an immunomodulator available as 5% cream, is an effective method of treatment of BD with cure rates ranging from 73% to 93%. It is applied once daily for up to 16 weeks. It is generally well tolerated, may cause erythema and crusting. (15) The benefit of these topical agents is in difficult to treat areas and large lesions where surgical treatment is inconvenient. However, PDT is more efficacious in larger lesions. (15, 16) This patient was started on topical 5-FU for the ease of topical therapy, since she was not willing for surgical methods of treatment. Newer modalities of treatment include topical diclofenac and lasers. (16) 
FINAL DIAGNOSIS
Bowen's disease of the right arm.
